By vgreene, 5 June, 2019 NTRK (nuerotrophic receptor tyrosine kinase) gene testing:1 to identify metastatic CRC pts who may be candidates for larotrectinib1
By vgreene, 5 June, 2019 BRAF V600E mutational analysis:1-3 of the primary colorectal CAs and/or the metastasis to determine tumor gene status (along w/ KRAS, NRAS mutation testing) individually or as part of next-gen sequencing NGS panel;1
By vgreene, 5 June, 2019 NRAS:1-3 If CRC pt being considered for anti-EGFR tx: Perform RAS mutational testing that includes KRAS and NRAS codons 12, 13 of exon 2; 59, 61 of exon 3; and 117 and 146 of exon 4 ("expanded" or "extended" RAS [ASCO recommendation; strength of ev: convi
By vgreene, 5 June, 2019 RAS (KRAS and NRAS) mutation testing:1-3 of the primary colorectal CAs and/or the metastasis to determine tumor gene status (along w/ BRAF V600E mutation testing) individually or as part of next-gen sequencing NGS panel;1
By vgreene, 5 June, 2019 Consider these assays as part of larger testing panel performed either initially or when routine EFGR, ALK, BRAF, and ROS1 testing is negative: